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Abstract
Objective: To assess the efficacy of cell‐free (cf)DNA screening for aneuploidy using
the automated system based on rolling circle replication.
Methods: A prospective study among women referred for invasive prenatal
diagnosis between July 2018 and December 2019. The plasma fraction was
extracted within 5 days from blood collection, stored at −20°C and cfDNA
measured between January and December 2019.
Results: A total of 805 women were recruited; 778 with singleton pregnancies and
27 twins. There were 48 Down syndrome, 25 Edwards syndrome and 3 Patau
syndrome cases. Overall, the no‐call rate was 2.6% (95% confidence interval
1.6%–3.9%) which reduced from 4.7% to 1.1% after relocation of the system
(p < 0.002) to ensure a constant ambient temperature below 25°C. In singletons the
Down syndrome detection rate (DR) was 100% (93%–100%) and false‐positive rate
(FPR) 0.14% (0.00%–0.79%). The Edwards syndrome DR was 96% (80%–100%) and
FPR 0.78% (0.29%–1.7%). One false‐positive had a confined placental trisomy 18
and the remaining five a z‐score requiring sample repetition; all the false‐positives
occurred before system relocation (p < 0.005). Patau syndrome DR and FPR were
67% (9.4%–99%) and 0.26% (0.03%–0.95%).
Conclusion: The cfDNA rolling circle method yields similar results to other methods
provided that room temperature is adequately controlled.
Key points
What is already known about this topic?
� Cell‐free DNA has considerably better screening performance than conventional tests
� Performance of the rolling circle method, in a single study, was similar to the three widely
used methods
What does this study add?
� Confirmation of the performance of the rolling circle method
� Demonstration that it can be readily incorporated into a conventional screening laboratory
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1 | INTRODUCTION
Currently, in Italy screening for Down and Edwards syndromes is by
either the conventional “Combined” test, based on first trimester
maternal serum pregnancy associated plasma protein (PAPP)‐A,
free‐β human chorionic gonadotrophin (hCG) and ultrasound nuchal
translucency (NT), or the “Integrated” test which incorporates first
trimester PAPP‐A and NT with second trimester serum markers – in
the Piedmont region they are α‐fetoprotein (AFP), unconjugated
estriol (uE3) and hCG.
A single maternal plasma marker of Down, Edwards and Patau
syndromes, cell‐free (cf)DNA, has considerably better screening
performance than all conventional multi‐marker screening tests.1
This has prompted us to consider an improvement of the screening
protocol in Piedmont. Three cfDNA policies can be considered:
“Primary” replacing conventional multi‐marker screening; “Second-
ary” offering cfDNA to women identified as high risk because of a
screen‐positive conventional test or another indication; and
“Contingent” offering it to those with screen‐positive/borderline
screen‐negative results, or borderline screen‐positive/screen‐nega-
tive results, and very high risk pregnancies directly referred to
invasive prenatal diagnosis. Several studies have shown that at
current cfDNA costs, Primary screening is expensive, Secondary
screening is cost‐neutral or better and Contingent screening is
affordable (see review2). Moreover, the Contingent approach would
have an additional economic and practical advantage if cfDNA testing
can be carried out in the same biochemical laboratory as the con-
ventional screening.
Three laboratory methods of cfDNA assay are currently in
widespread use: whole‐genome massively parallel sequencing (MPS)
to sequence and count large numbers of unique cfDNA fragments
and assign them to the chromosome of origin; a similar MPS
approach but targeting specific chromosome regions of interest for
enrichment and amplification; and analyzing single nucleotide poly-
morphisms thus determining the relative quantitative contributions
of maternal and fetal DNA in the plasma. These methods require
specialized equipment and staff as facilities for polymerase chain
reaction (PCR) and massive sequencing not generally available in a
biochemical screening laboratory.
Recently, a new method has been developed which incorporates
target regions into circular DNA that can undergo rolling circle
replication, fluorophore labeling of the products, and detection
following nanoparticle filtration.3 From the only published clinical
study this seems to have a screening performance similar to that of
the other methods4 with the advantage of being highly automated
without requiring next generation sequencing expertise.
This study was carried out in the Regional referral center for
prenatal screening of Piedmont. The aim was to investigate the
efficacy of the new automated cfDNA assay in a cohort of high risk
women attending prenatal invasive diagnosis for different indications
thus comparing the results of the non‐invasive test with the fetal
karyotype. Most women had already had Combined or Integrated
tests and the rest were tested retrospectively so as to estimate
cfDNA efficacy in women who would be selected in a Contingent




This was a prospective study carried out among women referred for
invasive prenatal diagnosis to the Ultrasound and Prenatal Diagnosis
Unit at St Anna Hospital between July 2018 and December 2019. All
women aged 18–55 referred after 10 weeks' gestation were
recruited to the study. Exclusion criteria were: severe hypotension
episodes or other conditions that may complicate the blood drawing
or other pregnancy related conditions; maternal aneuploidy; cancer;
and invasive prenatal diagnosis earlier in pregnancy.
2.2 | Blood samples
For those agreeing to participate in the study a 10 ml blood sample
was collected in a blood collection tube (Streck®) and sent to the
Prenatal Screening laboratory for processing, storage and analysis.
Women referred for chorionic villus sampling (CVS) without having
had conventional screening were included in the study provided they
agreed to have a retrospective Combined test in which case a further
2 ml of blood was collected for serum markers testing. Such women,
as well as those who had already had a Combined test, were also
asked to have an Integrated test. In such cases a further 2 ml of blood
was collected for serum marker testing and a second blood sample
was taken three weeks later. Women referred for amniocentesis
without having had a conventional screening test were not included
in the study. The results of these screening tests were not used
clinically.
2.3 | Cytogenetics
Genetic analysis of samples obtained at amniocentesis or CVS was
performed in the Medical Genetics Unit. Diagnosis was mostly based
on karyotyping whereas a smaller number had array comparative
genomic hybridization or trisomies assay by quantitative fluorescent
PCR (QF‐PCR). In a very small number of pregnancies the fetal ma-
terial was insufficient for karyotyping and the normal diploid status
was assessed on the basis of clinical outcome.
2.4 | cfDNA test
Plasma was extracted using a double centrifugation protocol of
1300 g for 30 min followed by 2400 g for 20 min. The plasma fraction
was transferred to an intermediate container following the first
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centrifugation step and to a Sarstedt tube after the second centri-
fugation. The plasma fraction was extracted within 5 days of storage
at room temperature following the blood draw and then stored at
−20°C until processing.
Testing was carried by the rolling circle method between January
and December 2019 using the automated Vanadis® system
(PerkinElmer) in 20 analytical runs. The system extracts and selects
thousands of unique DNA fragments from the target chromosomes
and converts them into large spherical DNA objects as described
previously.3 These objects were counted by a simple digital readout.
After automated quality assessment, the results were classified as
high risk or low risk according to the z‐score. The z‐score cut‐offs
were 3.50 for chromosome 21 and 3.15 for chromosomes 18 and
13. Before the Vanadis system was installed in the laboratory, cfDNA
was extracted from plasma using the Microlab STARlet workstation
(Hamilton) (71.4% of samples) while testing was completed with the
Vanadis system. Samples that failed quality assessment were re-
ported as no‐calls. The cfDNA results were not used clinically.
Laboratory technicians, in training biologists and health man-
agers had a one‐week training course on site. Three technicians were
involved in the study and worked in pairs, dedicating part of their
time over three days for each of the 20 analytical runs.
Screening performance of cfDNA was assessed in terms of the
no‐call rate and, in the accepted samples, the detection rate (DR) and
false‐positive rate (FPR) for each syndrome. The DR was the pro-
portion of affected pregnancies with high risk results for the corre-
sponding trisomy. The FPR was the proportion of pregnancies
without that syndrome, including those with other aneuploidies, with
high risk results for the corresponding trisomy.
During the course of the study it was noticed that the quality of
analytic runs was systematically decreased possibly affecting results,
although not all runs failed the quality control criteria. This was
investigated and high room temperature (>25°C) during the summer
months exceeded the requirements set for the instruments. During
the investigation, a part of the Vanadis Extract® instrument (EXU)
was replaced and additional air conditioning was installed in July
2019. Because the problem persisted, the Vanadis system was relo-
cated to a different laboratory space in September 2019. Screening
performance was assessed separately in the runs before and after
relocation of the system to the new laboratory.
2.5 | Conventional screening
Maternal serum PAPP‐A and free‐β hCG (Delfia Xpress, Perki-
nElmer), AFP, uE3 and hCG (AutoDELFIA, PerkinElmer) assays were
performed in the Prenatal screening laboratory. The levels of these
markers, together with the NT measurement, information on
maternal age, gestational age, maternal weight, smoking status,
assisted reproduction and insulin‐dependent diabetes were used to
compute the risk of Down and Edwards syndrome using the Alpha
Software (Logical Medical Systems). The same laboratory and soft-
ware systems were used to calculate risks in women whose
additional blood samples were retrospectively tested; for women
who already had an Integrated test, the blood sample was taken from
storage for free‐β hCG testing in order to complete a Combined test.
Results were classified as borderline if the risk of Down syndrome
was in the range 1 in 100‐1 in 2500 at term or the risk of Edwards
syndrome was 1 in 100‐1 in 1000.
3 | RESULTS
A total of 805 women were recruited to the study and the charac-
teristics of their pregnancies are summarized in Table 1. There were
778 singletons and 27 twins including five “vanishing” twins, that
spontaneously reduced to singletons before recruitment; of the non‐
vanishing twins 9 were mono‐chorionic, 10 dichorionic and three
with unknown chorionicity. The series included 48 pregnancies
affected by Down syndrome, one of which was a twin that had
reduced to a singleton, 25 Edwards syndrome and 3 Patau syndrome.
Among pregnancies without any of the three common trisomies, 5.5%
(40/729) had other chromosomal or genomic variants (28 pathogenic,
including placental mosaicisms, 6 benign and 6 of uncertain signifi-
cance); 5% (35/703) in singletons and 19% (5/26) in twins. Of those
enrolled in the study, four women refused the planned invasive
prenatal diagnosis, and in two cases the fetal cell culture failed. With
respect to these six cases, five women had an unaffected pregnancy
on the basis of clinical examination of the infant whereas one fetus
had ultrasound sign of Patau syndrome (holoprosencephaly) and the
pregnancy was terminated.
There were 438 women who had not had conventional screening
before enrollment and except for 9, all singletons, including 2 with
Down syndrome, they were screened as part of the study. Of the 796
screened before or subsequently, a Combined test was carried out in
782 and an Integrated test in 515, with both tests performed in 501
cases.
Table 2 shows for singletons the no‐call rate according to diag-
nosis. The rates are shown for all women, separately for the period
before and after the Vanadis system was relocated, and separately
for those with and without borderline conventional screening results
(i.e., risk between 1 in 100 and 1 in 2500 for Down syndrome or 1 in
1000 Edwards syndrome). The overall no‐call rate was 2.6% (20/778;
95% confidence interval [CI] 1.6%–3.9%). There was no statistically
significant difference in this rate according to diagnosis or the
screening result. But the relocation of the Vanadis system was
associated with a statistically significant reduction in no‐calls from
4.7% to 1.1% (15/322 compared with 5/456; p < 0.002, Chi‐squared
test).
Table 3 shows the DR and FPR in the 758 singleton pregnan-
cies after excluding the no‐calls. As in Table 2 the results are shown
for all women and broken down into subgroups. All Down syndrome
pregnancies were detected by cfDNA with only one false‐positive
result which had a chromosome 21 z‐score of 3.62, just above
the cut‐off, while in the true‐positive singleton pregnancies the
z‐score was 7.35–37.7 (median 16.59). The DR for Edwards
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syndrome was lower (96%) due to one false‐negative cfDNA result
but the overall false‐positive was considerably higher. All six false‐
positives occurred before the instrument was moved (p < 0.005).
One of them was indeed a true chromosome 18 trisomy confined to
the placenta (47,XX,+18 in 20 metaphases) while the karyotype on
amniotic fluid cells was normal without any evidence of fetal
mosaicism (46,XX in 32 metaphases and two signals for chromo-
some 18 centromere in 115 interphase nuclei by FISH assay). The
other five false‐positive results had a chromosome 18 z‐score of
3.43–4.25 compared with 4.25–19.78 in the true‐positive singleton
pregnancies (median 9.11). Of the three Patau syndrome cases one
was a cfDNA false‐negative and there were two false‐positives.
None of the affected pregnancies had a false‐positive result for a
different syndrome. There were no statistically significant differ-
ences in the FPRs between those with and without borderline
conventional screening results.
The cfDNA tests on the 27 twins did not result in any no‐calls,
the Down syndrome case (a vanishing twin) had a true‐
positive result and all the unaffected pregnancies had true‐
negative results.
TAB L E 1 Patient and pregnancy characteristics
Characteristic Value
Maternal age (years) Median (IQR) 36 (33–39)
Gestational age at CVS (days) Median (IQR) 85 (82–89)
Gestational age at amniocentesis (days) Median (IQR) 117 (113–126)
Maternal weight (kg) Median (IQR) 62 (55–70)
Origin Italy 632 (78.5%)
Other European 88 (10.9%)
Africa 38 (4.7%)
Elsewhere or unknown 47 (5.8%)
Fetuses Singleton 778 (96.6%)
Twin 27 (3.4%)
Of which vanishing twin 5 (0.6%)
Main reason for referral NT, positive biochemical screening and/or NIPT done elsewhere 360 (44.7%)
Advanced maternal age onlyb 236 (29.3%)
Recurrence risk for chromosomal, genomic or genetic diseases 122 (15.2%)
Ultrasound fetal abnormalities 66 (8.2%)
Infection and other 21 (2.6%)




Genetic diagnosis Karyotype 743 (92.3%)
Array CGH or QF‐PCRa 39 (4.8%)
Both 17 (2.1%)
Not done or failure 6 (0.7%)
Screening testc Combined test only 281 (34.9%)
Integrated test only 14 (1.7%)
Both 501 (62.2%)
Not done/incomplete 9 (1.1%)
Abbreviations: CGH, comparative genomic hybridization; CVS, chorionic villus sampling; IQR, inter‐quartile range; NIPT, non invasive prenatal testing;
NT, nuchal translucency; QF‐PCR, quantitative fluorescent polymerase chain reaction.
aOnly one QF‐PCR was performed.
bAge ≥35 is currently an indication, regardless of the screening result if done, although this policy is about to change.
cBefore the study or subsequently.
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4 | DISCUSSION
This study shows a considerable screening performance for the new
highly automated method of cfDNA testing. A high degree of auto-
mation, obviating the need for expertise in next generation
sequencing, makes the method suitable for biochemical screening
laboratories.
The singleton Down syndrome DR of 100% (95% CI 93%–100%)
and FPR of 0.14% (95% CI 0.00%–0.79%) are similar to that found in
the only other published study of testing clinical samples using the
Vanadis method with rates of 100% (112/112, 95% CI 97%–100%)
and 0.00% (0/1037, CI 0.00%–0.36%).4 In a meta‐analysis of 47
published studies using other cfDNA methods the weighted pooled
estimate of DR was 99.7% (95% CI: 99.1%–99.9%) and FPR 0.04%
TAB L E 2 Singleton pregnancies: cfDNA no‐call rate according to genetic/clinical diagnosis; all women analyzed with the NIPT Vanadis
system, and broken down by timing of the system relocation or conventional test result
Down syndrome Edwards syndrome Patau syndrome Unaffected or other
All analyzed cases 3/47 (6.4%)a 0/25 (0.0%) 0/3 (0.0%) 17/703 (2.4%)a
Vanadis system relocation
‐ Before 1/5 (20%) 0/5 (0.0%) 0/2 (0.0%) 14/310 (4.5%)b
‐ After 2/42 (4.8%) 0/20 (0.0%) 0/1 (0.0%) 3/393 (0.8%)b
Combined teste
‐ Borderline 0/10 (0.0%) 0/6 (0.0%) 0/1 (0.0%) 7/366 (1.9%)c
‐ Other 2/35 (5.7%) 0/19 (0.0%) 0/2 (0.0%) 9/317 (2.8%)c
Integrated teste
‐ Borderline 0/2 (0.0%) 0/3 (0.0%) 0/0 (–) 7/222 (3.2%)d
‐ Other 0/2 (0.0%) 0/4 (0.0%) 0/0 (–) 8/259 (3.1%)d
Abbreviations: cfDNA, cell‐free DNA; NIPT, non invasive prenatal testing.
aNo significant difference (p = 0.10, Chi‐squared test).
bSignificant (p < 0.002).
cNo significant difference (p = 0.42).
dNo significant difference (p = 0.97).
eNeither Combined nor Integrated tests available for 9 cases‐2 with Down syndrome and 7 unaffected or other.
TAB L E 3 Singletons – cfDNA detection and false‐positive rate according to genetic/clinical diagnosis; all women with Vanadis NIPT
results, and broken down by timing of the system relocation or conventional test resulta
Down syndrome Edwards syndrome Patau syndrome
Detection rate False‐positive rate Detection rate False‐positive rate Detection rate False‐positive rate
All NIPT with results 44/44 (100%) 1/714 (0.14%) 24/25 (96%) 6/733 (0.78%) 2/3 (67%) 2/755 (0.26%)
Vanadis system relocation
‐ Before 4/4 (100%) 0/303 (0.00%) 5/5 (100%) 6/302 (2.0%)b 1/2 (50%) 0/305 (0.00%)
‐ After 40/40 (100%) 1/411 (0.24%) 19/20 (95%) 0/431 (0.00%)b 1/1 (100%) 2/450 (0.44%)
Combined testc
‐ Borderline 10/10 (100%) 0/366 (0.00%) 5/6 (83%) 3/370 (0.81%) 1/1 (100%) 1/375 (0.27%)
‐ Other 33/33 (100%) 1/329 (0.30%) 19/19 (100%) 3/343 (0.87%) 1/2 (50%) 1/360 (0.28%)
Integrated testc
‐ Borderline 2/2 (100%) 0/218 (0.00%) 3/3 (100%) 1/217 (0.46%) 0/0 (–) 1/220 (0.45%)
‐ Other 2/2 (100%) 1/257 (0.39%) 4/4 (100%) 4/255 (1.6%) 0/0 (–) 0/259 (0.00%)
Abbreviations: cfDNA, cell‐free DNA; NIPT, non invasive prenatal testing.
aNo‐calls are excluded; the false‐positive rate denominator is all results excluding those from pregnancies with that syndrome.
bSignificant (p < 0.005, Chi‐squared test).
cNeither Combined nor Integrated tests available for 9 cases – 2 with Down syndrome and 7 unaffected or other.
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(0.02%–0.07%).1 The meta‐analysis included both prospective studies
on samples drawn in conventional screening programs and retro-
spective studies, in women with samples mostly drawn before
invasive prenatal diagnosis. Prospective studies are affected by
incomplete follow‐up and “viability” bias due to the inclusion of
detected non‐viable cases. Including just the 22 retrospective studies
the overall, pooled but not weighted, DR was 99.3% (95% CI 98.6%–
99.7%) and FPR 0.11% (95% CI 0.06%–0.18%).5
The singleton Edwards syndrome DR was 96% (95% CI
80%–100%) and FPR 0.78% (95% CI 0.29%–1.7%). By comparison, in
the other Vanadis clinical study the rates were 89% (32/36, 95% CI
74%–97%) and 0.48% (5/1037, CI 0.16%–1.1%) respectively4; and in
themeta‐analysis of retrospective studies 97% (95%CI94%–98%) and
FPR 0.09% (95%CI 0.04%–0.16%) respectively.5Whilst the CIs for the
DRs using the new method overlap with those for the other methods,
the FPR in the current study is relatively high and the lower confidence
limit exceeds the upper limit for the other methods. However, one
false‐positive result occurred in a case of chromosome 18 trisomy
confined to the placenta while fetal cells from amniotic fluid had
normal karyotype thus representing discordance between CVS
and amniocentesis results. The remaining five false‐positive results
had chromosome 18 z‐scores within a borderline zone where the
Vanadis kit instructions recommend repeating the test on a second
sample. The current study did not allow test repetition because each
woman provided only one sample. Moreover, with outcome based on
amniotic fluid karyotype – three out of five false‐positives – placental
mosaicism cannot be excluded, nor maternal chromosomal abnor-
malities or residual cfDNA derived from a vanishing twin.
The singleton Patau syndrome DR and FPR were 67% (95% CI
9.4%–99%) and 0.26% (95% CI 0.03%–0.95%); the clinical Vanadis
study 100% (10/10, 95% 69%–100%) and 0.10% (1/1037, CI
0.00%–0.54%)4; and the meta‐analysis of retrospective studies 90%
(95% CI 83%–95%) and FPR 0.18% (95% CI 0.11%–0.28%).5 The poor
Patau syndrome DR was evaluated on a very limited number of cases;
in a Contingent cfDNA approach such pregnancies might be referred
for an invasive procedure because of their high risk conventional
screening test results.
Overall, among singletons there were 20 no‐calls, a rate of 2.6%
(95% CI 1.6%–3.9%). In the meta‐analysis 26 studies reported a
singleton no‐call rate, after excluding failures due to blood collection
and transportation to the laboratory.1 The median no‐call rate was
2.3% and for studies giving the reason for no‐calls, in about half the
samples the reason was a fetal fraction (FF), the proportion of cfDNA
derived from the fetus, below 4%. This cut‐off is widely used because
the cfDNA test is expected to be less accurate at such levels.
However, unlike other cfDNA methods, Vanadis does not
measure FF. This is because of reduced assay variability due to not
having a DNA amplification step which allows test accuracy at FF
below 2%.3 Moreover, the measurement of FF itself has been shown
to introduce considerable variability.6 In the other prospective study
of the Vanadis method the no‐call rate was only 0.42% (5/1200, 95%
CI 0.14%–0.97%).4 The much higher no‐call rate in the current study
is attributable to the decreased quality of assay runs in the early part
of the study, possibly due to high temperature in the laboratory
space. After the system had been moved to a more suitable space the
no‐call rate was 1.1% (95% CI 0.36%–2.5%) and consistent with
the other study. The difference in no‐call rate before and after the
move cannot be attributed to factors such as gestational age and
maternal weight, which are known to influence FF. In fact, first
trimester samples analyzed in the two time periods belonged to
women with a median gestational age of 86 and 85 days, respectively
(p = 0.13, Wilcoxon Rank Sum Test) and the median maternal weight
was 63.0 and 61.5 kg (p = 0.55, Wilcoxon Rank Sum Test).
The DRs reported in the meta‐analyses and in the two studies
using the Vanadis method exclude no‐calls but in practice the effec-
tive DR will depend on how no‐calls are treated. Referring all of them
for invasive prenatal diagnosis, as some medical bodies currently
suggest,7 will increase the effective DR but considerably increase the
FPR, taking no further action will reduce the effective DR and FPR,
whilst testing a repeat blood sample will resolve about two‐thirds of
no‐calls due to low FF.8 The resolution of no‐calls using the Vanadis
method has been assessed in 8 out of 545 samples (1.5%) tested in
Finland; in the repeated samples only one was a no‐call.9 It is unclear
how many of the studies in the meta‐analysis reported no‐call rates
after repeat testing but neither of the Vanadis studies had repeat
testing as only one sample was available.
As with conventional multi‐marker screening, the performance
of cfDNA testing in twin pregnancies is expected to be less than in
singletons due to the underrepresentation of the supernumerary
chromosome in twins discordant for a trisomy. Although in theory
detection in twins should be lower than in singletons, it can be offset
to some extent by a higher FF in twins, estimated to be one‐third in
one study.10 In fact, in a meta‐analysis of 11 published studies of
discordant twins5 the DRs were similar to singletons: Down
syndrome 97% (57/59, 95% CI 88%–100%), Edwards syndrome 89%
(8/9, 95% CI 0.52%–100%), and Patau syndrome 100% (2/2, 95% CI
16%–100%). The FPR was 0.05% (1/1952, 95% CI 0.00%–0.58%). FF
may differ between the two fetuses and a policy has been adopted
whereby both FFs are estimated and the smaller is used to decide on
a no‐call. This will lead to a higher no‐call rate in twins than single-
tons; 9.4% and 2.9% in one study.11 The current study had too few
twins to make any comparisons and the previous clinical study of the
Vanadis method excluded twins.
From a practical perspective a known vanishing twin might be a
contra‐indication for cfDNA testing but the five in the current study
were included as twins. There were no false‐positives or false‐
negatives and so if they had been classified as singletons the
no‐call, DR and FPR would not have been materially altered.
The screening performance of cfDNA using any of the four
methods is substantially higher than the Combined or Integrated tests.
For example, at 11 weeks' gestation the Combined test model
predicted Down syndrome DR – for a 5% FPR using parameters based
on meta‐analysis and a standardized maternal age distribution – is
87%.12 For the Integrated test the predicted DR increases to 94%
although this would be lower without second trimester inhibin‐A, as in
Piedmont.
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When considering a Contingent cfDNA screening policy it is
relevant to assess the test performance in those with borderline
conventional screening results (i.e., risk 1 in 100‐1 in 2500 for
Down syndrome or 1 in 1000 Edwards syndrome) compared with
the remainder. This study found a lower overall no‐call rate in the
Combined test borderline group of 1.8% (7/383) compared to the
screen‐negatives where it was 2.9% (11/373) although this differ-
ence did not reach statistical significance (p = 0.31, Chi‐squared
test). There was no material difference in no‐call rate according
to the Integrated test results. There were too few affected preg-
nancies with borderline results to compare DRs but there were
sufficient unaffected or other pregnancies to compare FPRs. Given
that a pregnancy with a syndrome could be a false‐positive for
another syndrome, the overall rate in the Combined test borderline
group was 1.1% (4/376) compared with 1.4% (5/362) in screen‐
negatives which was not statistically significant (p = 0.69). For the
Integrated test borderline group, the corresponding rates were
1.4% and 1.9% (p = 0.62).
The Contingent cfDNA policy examined here is based on
women with borderline Down or Edwards syndrome risks being
offered a cfDNA test and those with risks above the cut‐offs being
referred directly for invasive prenatal diagnosis. Since the study
was based on women referred for invasive testing, many of whom
had a positive conventional screening test as the indication, it
cannot be used to directly estimate the DR and FPR of the
Contingent cfDNA policy. However, published model predicted es-
timates are available in the literature and local details such as the
maternal age distribution, type of conventional screening test and
specific cut‐off risks defining the borderline are unlikely to make a
substantial difference.
The rolling circle method, in common with other cfDNA tests, can
also accurately detect fetal gender.4 The current study is focused on
using the method in screening for aneuploidy and gender determi-
nation was not investigated.
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